Search

Background: Liver transplantation has improved patients' survival rates and quality of life (QoL). This study investigated the effect of liver transplantation and model for end-stage liver disease (MELD) score on patients' QoL at Shiraz Organ Transplantation Center. Materials and Methods: This perspective longitudinal study was conducted among 40 liver transplant candidates at Shiraz Organ Transplant Center. Inclusion criteria were patients who were 12 years or older, able to answer the questions and willingness to participate. If they had received multi-organ transplant and had mental or physical disabilities, we excluded them from the study. They were interviewed by the same researcher in the transplant clinic before transplantation, 1 and 6 months after transplantation. The participants completed the data collection form and Short Form-36 questionnaire via face-to-face interview. The data collecting form consist of demographic and medical information. Medical information was collected from Shiraz Organ Transplant Center. Results: Mean age of participants was 41.18 ± 14. By comparing QoL dimensions, a significant difference was found between before and after transplantation (P < 0.001), except in General Health dimension (P = 0.711). There was no statistically significant relationship between MELD score and QoL after liver transplantation (P > 0. 05). Conclusion: Liver transplantation improves patients' quality life with end-stage liver disease. MELD scores do not depict QoL after liver transplantation.

Background: Patients with end-stage liver disease frequently acquired complex disorders in hemostasis secondary to liver dysfunction. Objectives: This study aims to determine the incidence of vascular complications associated with central venous catheterization (CVC) in patients with coagulopathy and liver disease. Methods and Subjects: This multicentric, retrospective, cross-sectional study was performed on 993 patients undergoing liver transplantation who required central venous access (CVA) for their clinical management between October 2006 and October 2016. The age, sex, most recent platelet count, prothrombin time, international normalized ratio (INR), activated partial thromboplastin time, site of central venous catheter placement, and bleeding complications were retrieved from their medical records. Results: In these 993 cases, the mean age was 57.46 (standard deviation = 7.46) years, and 635 (63.9%) were male. Selected sites were the internal jugular (n = 889; 89.5%), subclavian (n = 93; 9.4%), and femoral (n = 11; 1.1%) veins. First attempt was successful in 925 cases (93.2%), in which 1 case had major bleeding, and 84 cases had minor bleeding. About 83% of the patients with liver failure take CVC procedure without any complications. None of the vascular complications occurred in 53% of the patients with low platelets and INR >1.5. Conclusion: We demonstrated major vascular complications following CVC in patients with liver disease and coagulopathy has low incidence in this audit. CVA procedures can be done safely in patients with disorders of hemostasis by skilled physicians who frequently perform these procedures.

Glomus tumor is a rare neoplasm of the distal extremities. It occurs very rarely in the deep visceral organs such as stomach, lung, pancreas, ovary, and liver. Herein, we report a very rare case of glomus tumor of the liver in a 50-year-old woman presenting with abdominal mass which was diagnosed after surgery. The tumor was large and cystic; however, the morphology was similar to the ordinary soft-tissue glomus tumor. Tumor cells were reactive with CD34 and SMA. The patient′s follow up failed to show any evidence of malignant behavior or tumor recurrence. This report is the third primary glomus tumor of the liver in the English literature.

The development of malignancies after solid organ transplants is a well-known complication. Cancer is associated with significant consequences for the organ transplant patient. It is expected that cancer will surpass cardiovascular complications as the leading cause of death in transplant patients within the next few years. We report on a 36-year-old male patient who developed mixed germ-cell testicular tumor seven years after liver transplantation for alcoholic cirrhosis. He was treated with orchiectomy, retroperitoneal lymph node dissection and post-operative chemotherapy.